Early response to vunakizumab and its baseline predictors in patients with moderate-to-severe plaque psoriasis: a post hoc analysis of a phase-III trial
Year: 2025
Type: article
Abstract: Background Exploring predictors of early response is meaningful to optimize treatment strategies of patients with psoriasis. However, predictors of early response to vunakizumab remain unidentified.Objective This study aimed to investigate the early response rates to vunakizumab and identify predictors in patients with moderate-to-severe plaque psoriasis.Methods Data were derived from a phase-III trial (NCT04839016), and 461 patients with moderate-to-severe plaque psoriasis receiving vunakizumab were included. Early response was defined as ≥50% improvement in the Psoriasis Area Severity Index (PASI 50) by week 2 of treatment.Results A total of 54.0% of patients achieved early response. The proportion of males with early response (71.1%) was lower than males without that (82.5%) (p = 0.004). Regarding patients who had previous local treatment, the proportion of patients with early response (77.1%) was lower than patients without that (85.4%) (p = 0.024). Male [adjusted odds ratio (OR)=0.558, p = 0.027] and previous local treatment (adjusted OR = 0.586, p = 0.039) independently predicted lower possibility of early response. The nomogram demonstrated good calibration performance (mean absolute error: 0.021) with a limited discriminative ability (C-index: 0.580).Conclusion Early response rate to vunakizumab was 54.0% in patients with moderate-to-severe plaque psoriasis, where female gender and naïve status to local therapy predicted early response.
Authors: Yangyiyi Yu, Jinrong Zeng, Jianyun Lu
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W4414516269